We are helping people
with dermatological
 disease live better lives.

Get to know Verrica

Innovation is in our DNA

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring real relief to patients, advancing accessible therapies to prescribers and payers, and providing peace of mind to parents and caregivers. Verrica is focused on innovation, changing the narrative around viral skin diseases, and making treatment a more efficient process for both physicians and patients.

Our Mission

Verrica Pharmaceuticals is committed to the development and commercialization of novel treatments that provide significant benefit for people living with skin diseases. Our clinical programs are developed with an understanding of the patient journey and the healthcare-provider landscape. It is our mission to develop treatment solutions for the millions of underserved patients who have had few options for satisfactory medical care and attention.

Learn more
Verrica Announces Proposed Public Offering
Verrica Announces Proposed Public Offering

November 20, 2024

Learn More
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

November 4, 2024

Learn More
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP 315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP 315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

October 31, 2024

Learn More
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

October 2, 2024

Learn More
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

September 4, 2024

Learn More
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 14, 2024

Learn More
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP 315 an Investigational Oncolytic Peptide Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP 315 an Investigational Oncolytic Peptide Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

August 14, 2024

Learn More
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP 315 for the Treatment of Basal Cell Carcinoma on August 14 2024
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP 315 for the Treatment of Basal Cell Carcinoma on August 14 2024

August 6, 2024

Learn More
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories Inc.
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories Inc.

July 1, 2024

Learn More
previous arrow
next arrow
Load More

Careers at Verrica

Listening, learning and leading the way, Verrica Pharmaceuticals values a  commitment to innovative dermatology therapeutics and the ability to deliver ideas and results with speed and agility. We foster an all-hands-on-deck mindset among our employees, enabling everyone with the voice and opportunity to take ownership of their work, and become a vital stakeholder with the company.

Learn more
Important News Regarding Fraudulent Activity
About Us
Our Medicines
Product Candidates
Investors & Media
Careers
Twitter Linkedin-in Facebook-f
© 2024 Verrica Pharmaceuticals.

Important News Regarding Fradulent Activity

IMPORTANT NOTICE

We recently became aware of what we deem to be unauthorized and fraudulent activity involving the distribution of false information and documentation regarding potential job opportunities at Verrica. Any communication purporting to be from Verrica or any of its employees, officers, or directors regarding a potential job opportunity with our company which includes a request for money, gifts, purchase of equipment, or your personal information is fraudulent and is not authorized by, nor sent on behalf of Verrica.

We list all current job opportunities on this website. Our employment processes involve personal interviews. Candidates who seek employment with us are never required to pay us or purchase any items for the company from their personal funds.

If you receive a request for money, your personal information, or that asks you to do anything that appears to be remotely suspicious in connection with an offer of employment with Verrica, please report this matter to careers@verrica.com. You also should report this matter to your local law enforcement authorities. If you were contacted by email from a Gmail or other email address, please contact that email provider.